Cell therapy company Chimeric Therapeutics (ASX:CHM) has provided additional information on its previously announced positive in vitro data for CHM 1301.

Microba Life Sciences (ASX:MAP) has announced that stage one activity screening for its autoimmune disease program has been completed on schedule with partner Ginkgo Bioworks.

The Albanese Government has officially opened the $392 million Industry Growth Program that includes medical science as one of its priority target areas.

AusBiotech has urged policy-makers to take a national approach to capability mapping and introduce targeted initiatives in response to the federal government’s discussion paper, Understanding our RNA potential.

Dimerix (ASX:DXB) has announced that Chinese National Medical Products Administration Center for Drug Evaluation has approved an Investigational New Drug application to commence recruitment for ACTION3 Phase 3 study of DMX-200 for focal segmental glomerulosclerosis kidney disease.

Health Minister Mark Butler has announced that the federal government will invest over $700,000 to support the development of a potential new treatment that targets a type of childhood brain cancer with no known cure or treatment options.

Australian antiviral drug development company Island Pharmaceuticals (ASX:ILA) has dosed the first cohort in its single ascending dose study for ISLA-101.

The Australian Cell & Gene Catalyst has issued its response to the federal government's health workforce scope of practice review.

AMR is an increasing global health priority, estimated to be directly responsible for 1.27 million deaths worldwide in 2019.

Australian company Race Oncology (ASX:RAC) has announced the appointment of Dr Daniel Tillett as its new chief executive officer.

The University of Queensland’s re-engineered clamp platform has produced a vaccine that is equally safe and virus-neutralising as an approved vaccine.

Alterity Therapeutics (ASX:ATH) has received binding commitments for a capital raising of $4.8 million before costs via a two-tranche placement of fully paid ordinary shares to Australian and international institutions and other unrelated sophisticated, professional or other exempt investors.

Orthocell (ASX:OCC) has announced the final results from its clinical study comparing OrthoATI to surgery to treat severe, chronic, treatment-resistant lateral epicondylitis.

QIMR Berghofer and Murdoch University researchers were announced as joint winners at AusBiotech 2023’s Early-Stage Innovation Forum held in Brisbane on 3 November.

Australian cell therapy company Chimeric Therapeutics (ASX:CHM) has announced that the ADVENT-AML Phase 1B clinical trial abstract was selected for presentation at the 2023 Annual Meeting of the American Society of Hematology.

Anteris Technologies (ASX:AVR) has reported 30-day data from the US Early Feasibility Study for DurAVR Transcatheter Heart Valve.

Respiratory imaging technology company 4DMedical Limited (ASX:4DX) has US FDA-received clearance for its CT-based ventilation product.